InnoCan Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OTCPK:INNP.F Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Role	Shares	Max Price
01 Nov 24	SellUS$11,458	Peter Bloch	Individual		72,222	US$0.17
06 Sep 24	SellUS$12,790	Peter Bloch	Individual		72,222	US$0.18

Insider Trading Volume

Insider Buying: INNP.F insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of INNP.F?
Owner Type	Number of Shares	Ownership Percentage
Institutions	528,000	0.184%
Individual Insiders	15,545,062	5.42%
Private Companies	49,726,311	17.3%
General Public	221,138,898	77.1%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.1%.

Top Shareholders

Top 9 shareholders own 22.93% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
17.3%	Solsken Limited	49,726,311	US$6.4m	0%	no data
2.29%	Ron Mayron	6,565,554	US$845.2k	27.2%	no data
1.8%	Iris Bincovich	5,161,344	US$664.4k	4.5%	no data
0.89%	Eyal Flom	2,553,055	US$328.7k	7.48%	no data
0.18%	Drh VermÖGensverwaltung GmbH	528,000	US$68.0k	0%	0.17%
0.15%	Roni Kamhi	444,444	US$57.2k	100%	no data
0.11%	Ralph C. Bossino	313,333	US$40.3k	27%	no data
0.11%	Nelson Halpern	303,666	US$39.1k	-15.7%	no data
0.071%	Joshua Lintern	203,666	US$26.2k	27%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/23 11:30
End of Day Share Price	2024/12/09 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

InnoCan Pharma Corporation is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution